Nordson Corp Stock Price, News & Analysis

Nordson (Nasdaq: NDSN) has completed the acquisition of Atrion , a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions. This strategic move expands Nordson's medical portfolio into new markets and therapies, supported by long-term secular growth trends. The acquisition, initially announced on May 28, 2024, aligns with Nordson's innovative precision technology focus and scalable growth framework.

Nordson will provide further details about the acquisition during its third quarter fiscal year 2024 webcast scheduled for Thursday, August 22, 2024, at 8:30 AM ET. The company, founded in 1954 and headquartered in Westlake, Ohio, leverages a direct sales model and applications expertise to serve global customers across consumer non-durable, medical, electronics, and industrial end markets.

Nordson (NDSN) has announced a 15% increase in its quarterly cash dividend, raising it to $0.78 per common share from $0.68. This marks the company's 61st consecutive year of annual dividend increases, placing it among an elite group of companies with the longest-running record of consecutive dividend increases. The dividend is payable on September 10, 2024, to shareholders of record as of August 27, 2024.

Nordson's CFO, Daniel Hopgood, highlighted the company's focus on customer satisfaction, innovation, and differentiation, combined with its Ascend strategy, as key factors in generating consistent cash flows and enabling shareholder value return. Nordson is an innovative precision technology company serving diverse end markets, including consumer non-durable, medical, electronics, and industrial sectors.

Nordson (Nasdaq: NDSN) has announced the release date for its third quarter fiscal year 2024 earnings. The company will publish its financial results on August 21, 2024, after the market closes. A quarterly webcast is scheduled for August 22, 2024, at 8:30 AM ET.

Investors can access the webcast through a provided link and a replay will be available on Nordson's investor website. Nordson, headquartered in Westlake, Ohio, is described as an innovative precision technology company with a scalable growth framework and division-led organization. The company serves global customers across various industries, including consumer non-durable, medical, electronics, and industrial end markets.

Nordson Electronics Solutions has consolidated its European operations into a new state-of-the-art facility in Valkenswaard, The Netherlands. This move integrates multiple sites from Deurne, Maastricht, and Hagenbach, Germany, into a central location to meet rising European customer demand. The new facility features a demonstration lab showcasing the latest equipment from ASYMTEK, MARCH, and SELECT product lines, offering solutions for conformal coating, fluid dispensing, plasma treatment, and selective soldering in electronics manufacturing.

The modern building incorporates environmental efficiency features such as solar panels and energy-conserving underfloor heating, aligning with Nordson 's sustainability commitment. Located in the Eindhoven area, the new site minimizes disruption to customers, partners, and suppliers while supporting customers backed by the European Chips Act to boost regional resilience.

Nordson (Nasdaq: NDSN) announced its agreement to acquire Atrion (Nasdaq: ATRI), a leader in medical infusion and cardiovascular technologies, for $460.00 per share in cash. This acquisition values Atrion at approximately $800 million and expands Nordson’s medical portfolio into new markets and therapies. Atrion generated about $169 million in revenue in 2023 and operates three FDA registered manufacturing facilities in the U.S.

The acquisition will be funded through cash on hand and newly issued financial debt and is expected to close before Nordson’s fiscal year-end in 2024, pending regulatory and stockholder approvals. The transaction is expected to generate significant synergies within the first two years of ownership.

The acquisition aligns with Nordson's strategy to leverage long-term growth drivers in the medical sector, including an aging population, increased healthcare spending, and the adoption of minimally invasive surgical techniques.

Nordson (Nasdaq: NDSN) reported its fiscal Q2 2024 results with sales of $651 million, matching last year's figure. Net income stood at $118 million, equating to $2.05 per diluted share, a slight decrease from the previous year's $128 million and $2.21 per share. Adjusted earnings were $2.34 per share, down from $2.45. EBITDA remained flat at $203 million, representing 31% of sales.

Segment-wise, Industrial Precision Solutions saw a 9% sales increase to $367 million, while Medical and Fluid Solutions experienced a 2% rise to $169 million. Advanced Technology Solutions, however, faced a 22% decline in sales to $115 million.

Nordson updated its full-year fiscal 2024 guidance to forecast flat to 2% revenue growth, with adjusted EPS expected to range between $9.35 and $9.75. Q3 sales are projected between $645 and $670 million, with adjusted EPS of $2.25 to $2.40.

Nordson (Nasdaq: NDSN) declared a third quarter cash dividend of $0.68 per share for fiscal year 2024, maintaining the same amount as the previous quarter. The company is known for its innovative precision technology and diverse end market exposure, including consumer non-durable, medical, electronics, and industrial markets.

Nordson (Nasdaq: NDSN) announced the release of its second-quarter fiscal year 2024 earnings on May 20, 2024. The company will host a webcast on May 21, 2024, at 8:30 AM ET. Nordson is a precision technology company with a direct sales model, serving global customers in various end markets.